Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR plus breast cancer: A secondary analysis of the SOFT trial.

被引：0
|
作者：
Brown, Lauren Claire
Luen, Stephen James
Molania, Ramyar
Caramia, Franco
Savas, Peter
VanGeelen, Courtney
Chic, Nuria
Fleming, Gini F.
Kammler, Rosita
Colleoni, Marco
Viale, Giuseppe
Speed, Terence Paul
Regan, Meredith M.
Francis, Prudence A.
Loi, Sherene
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Chicago, Chicago, IL USA
[3] Int Breast Canc Study Grp, Bern, Switzerland
[4] European Inst Oncol, Milan, Italy
[5] Univ Milan, European Inst Oncol, Milan, Italy
[6] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[7] Dana Farber Canc Inst, Boston, MA USA
[8] Int Breast Canc Study Grp, Boston, MA USA
[9] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR plus breast cancer in the SOFT trial
    O'Regan, Ruth
    Zhang, Yi
    Fleming, Gini F.
    Francis, Prudence
    Kammler, Roswitha
    Viale, Giuseppe
    Lang, Istvan
    Ezquerra, Meritxell Bellet
    Bonnefoi, Herve R.
    Loi, Sherene
    Colleoni, Marco
    Schnabel, Catherine A.
    Treuner, Kai
    Regan, Meredith
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial.
    Bartlett, John M. S.
    Xu, Keying
    Wong, Jenna
    Pond, Gregory Russell
    Zhang, Yi
    Spears, Melanie
    Salunga, Ranelle C.
    Mallon, Elizabeth
    Taylor, Karen J.
    Hasenburg, Annette
    Markopoulos, Christos
    Dirix, Luc Yves
    Seynaeve, Caroline M.
    Van de Velde, Cornelis J. H.
    Rea, Daniel William
    Schnabel, Catherine A.
    Treuner, Kai
    Bayani, Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Ohnstad, Hege O.
    Borgen, Elin
    Falk, Ragnhild S.
    Lien, Tonje G.
    Aaserud, Marit
    Sveli, My Anh T.
    Kyte, Jon A.
    Kristensen, Vessela N.
    Geitvik, Gry A.
    Schlichting, Ellen
    Wist, Erik A.
    Sorlie, Therese
    Russnes, Hege G.
    Naume, Bjorn
    BREAST CANCER RESEARCH, 2017, 19
  • [4] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Hege O. Ohnstad
    Elin Borgen
    Ragnhild S. Falk
    Tonje G. Lien
    Marit Aaserud
    My Anh T. Sveli
    Jon A. Kyte
    Vessela N. Kristensen
    Gry A. Geitvik
    Ellen Schlichting
    Erik A. Wist
    Therese Sørlie
    Hege G. Russnes
    Bjørn Naume
    Breast Cancer Research, 19
  • [5] Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
    Sanchez Bayona, R.
    Tolosa, P.
    Alba Bianchi, M.
    Madariaga Urrutia, A.
    Teran, S.
    Rey Cardenas, M.
    Lema Roso, L.
    Ruano, Y.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S143 - S144
  • [6] Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER plus early breast cancer (EBC): An ABCSG study
    Gnant, M.
    Filipits, M.
    Mlineritsch, B.
    Dubsky, P.
    Jakesz, R.
    Kwasny, W.
    Fitzal, F.
    Rudas, M.
    Knauer, M.
    Singer, C.
    Greil, R.
    Ferree, S.
    Storhoff, J.
    Cowens, J. W.
    Schaper, C.
    Liu, S.
    Nielsen, T.
    CANCER RESEARCH, 2012, 72
  • [7] Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
    Kelly, Catherine M.
    Bernard, Philip S.
    Krishnamurthy, Savitri
    Wang, Bailiang
    Ebbert, Mark T. W.
    Bastien, Roy R. L.
    Boucher, Kenneth M.
    Young, Elliana
    Iwamoto, Takayuki
    Pusztai, Lajos
    ONCOLOGIST, 2012, 17 (04): : 492 - 498
  • [8] PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
    Conte, Pier Franco
    Griguolo, Gaia
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Brandes, Alba Ariela
    Frassoldati, Antonio
    Cavanna, Luigi
    Musolino, Antonino
    Giotta, Francesco
    Rimanti, Anita
    Garrone, Ornella
    Galvan, Patricia
    Maristany, Fara Braso
    Orvieto, Enrico
    Urso, Loredana
    Maiorana, Antonino
    Balduzzi, Sara
    D'Amico, Roberto
    Guarneri, Valentina
    Prat, Aleix
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR plus breast cancer in the TEAM trial
    Bartlett, J. M.
    Xu, K.
    Wong, J.
    Pond, G.
    Zhang, Y.
    Spears, M.
    Salunga, R.
    Mallon, E.
    Taylor, K. J.
    Hasenburg, A.
    Markopoulos, C.
    Dirix, L. Y.
    Seynaeve, C.
    van de Velde, C.
    Rea, D.
    Schnabel, C. A.
    Treuner, K.
    Bayani, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S602 - S602
  • [10] Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR plus breast cancer in the TEAM trial
    Bartlett, John M. S.
    Xu, Keying
    Wong, Jenna
    Pond, Gregory R.
    Zhang, Yi
    Spears, Melanie
    Salunga, Ranelle
    Mallon, Elizabeth
    Taylor, Karen J.
    Hasenburg, Annette
    Markopoulos, Christos
    Dirix, Luc
    Seynaeve, Caroline
    van de Velde, Cornelis J. H.
    Rea, Daniel
    Schnabel, Catherine A.
    Treuner, Kai
    Bayani, Jane
    CANCER RESEARCH, 2023, 83 (05)
12345